|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.40 EUR | 0.00% |
|
+1.29% | - |
| Nov. 13 | Biotest AG Obtains Approval for New Human Fibrinogen Prufibry®? in Germany | CI |
| Oct. 09 | Biotest Ag Announces the Official Launch of Yimmugo | CI |
| Capitalization | 1.34B 1.57B 1.25B 1.18B 2.17B 143B 2.37B 14.63B 5.67B 67.23B 5.91B 5.78B 245B | P/E ratio 2025 * |
-
| P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 2B 2.35B 1.87B 1.76B 3.24B 213B 3.54B 21.86B 8.48B 100B 8.83B 8.64B 367B | EV / Sales 2025 * |
2.81x | EV / Sales 2026 * | - |
| Free-Float |
51.43% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More press releases
More news
| 1 week | +1.29% | ||
| Current month | +1.95% | ||
| 1 month | -4.85% | ||
| 3 months | +6.08% | ||
| 6 months | +6.08% |
| 1 week | 31.4 |  | 31.6 |
| 1 month | 29 | | 32.2 |
| Current year | 27.1 | | 34 |
| 1 year | 27.1 | | 34 |
| 3 years | 27.1 | | 34 |
| 5 years | 27.1 | | 34 |
| 10 years | 27.1 | | 34 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jörg Schüttrumpf
CEO | Chief Executive Officer | 51 | 2025-05-27 |
Oliver Hein
CMP | Compliance Officer | - | 2016-12-31 |
Christian Polus
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jürgen Heilmann
BRD | Director/Board Member | 63 | 2011-08-31 |
| Chairman | 70 | 2022-05-04 | |
Dirk Schuck
BRD | Director/Board Member | - | 2022-04-05 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +1.29% | - | - | 1.57B | |
| -0.74% | +3.19% | +1.37% | -0.84% | 76.06B | |
| +2.86% | -0.09% | -33.73% | -38.08% | 58.92B | |
| +1.38% | +69.20% | +69.20% | +69.20% | 53.01B | |
| -2.24% | -4.93% | +30.25% | +221.80% | 52.48B | |
| +0.93% | -3.97% | +16.04% | -40.22% | 25.54B | |
| +1.85% | -7.39% | +127.81% | +163.37% | 18.76B | |
| -0.72% | -6.94% | +39.18% | +15.08% | 18.73B | |
| -4.52% | -5.15% | +36.59% | +1,036.48% | 15.67B | |
| +1.46% | +2.05% | +173.37% | +704.60% | 14.48B | |
| Average | +0.03% | -1.84% | +51.12% | +236.82% | 33.52B | |
| Weighted average by Cap. | +0.19% | -0.72% | +29.97% | +125.19% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 712M 836M 665M 626M 1.15B 75.71B 1.26B 7.76B 3.01B 35.69B 3.14B 3.07B 130B | - |
| Net income | 59.46M 69.8M 55.54M 52.26M 96.21M 6.32B 105M 648M 251M 2.98B 262M 256M 10.87B | - |
| Net Debt | 663M 778M 619M 583M 1.07B 70.5B 1.17B 7.23B 2.8B 33.23B 2.92B 2.86B 121B | - |
More financial data
* Estimated data
Employees
2,495
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 31.40 € | 0.00% | 110 |
| 25-12-11 | 31.40 € | 0.00% | 1,822 |
| 25-12-10 | 31.40 € | 0.00% | 65 |
| 25-12-09 | 31.40 € | -0.63% | 0 |
| 25-12-08 | 31.60 € | +1.94% | 55 |
End-of-day quote Hanseatische Wertpapierboerse Hamburg, December 10, 2025
More quotes
Net sales - Rate of surprise
- Stock Market
- Equities
- BIO3 Stock
Select your edition
All financial news and data tailored to specific country editions
